This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Measurement of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) predicted the 30-year cardiovasculardisease risk among women enrolled in the Women’s Health Study.
milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo.
The objective of this study was to examine the prospective association between plasma RvD2 and the risk of atherosclerotic cardiovasculardisease (ASCVD) at the population level.Methods and ResultsA cohort of 2633 community‐dwelling individuals aged 35–60 years was followed for 8 years in this study. P<0.001).
Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovasculardisease. Journal of the American Heart Association, Ahead of Print. Barriers include poor adherence, clinical inertia, concern for side effects, cost, and complex prior authorization processes.
This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)–Inhibiting Regimen (CLEAR) Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovasculardisease.
AimsHistorically, atherosclerotic cardiovasculardisease (ASCVD) risk profile mitigation has had a predominant focus on low density lipoprotein cholesterol (LDL-C). This relationship is complicated by the co-existence of low high-density lipoprotein cholesterol.
Background Cardiovasculardisease (CVD) risk increases with age. Statins reduce cardiovascular risk but their effects are less certain at older ages. CTTC individual participant data and other meta-analyses informed statins’ effects on cardiovascular risks, incident diabetes, myopathy and rhabdomyolysis.
BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. The resulting cholesterol crystals activate the NLRP3 (NOD‐like receptor protein 3) inflammasome, leading to inflammation and cardiovasculardiseases. mg/dL versus 97.9±37.6
Exercise prevents and reverses cardiovasculardisease, but whether high-intensity exercise training (HIIT) is safe and effective for adults after minimally invasive heart surgery is unknown. Exercise is a wonder drug for cardiovasculardisease (CVD) prevention and reversal. Cardiac rehab works wonders.
It is well known that high levels of low-density lipoprotein (LDL) cholesterol, known as the “bad” cholesterol, heighten cardiovascular risk. A total of 154 patients (median age 62 years, 42% women) with high triglyceride levels and other risk factors for cardiovasculardisease participated in the study at 24 sites in the U.S.
There are numerous effective medications for modifying CAD but new pharmacologic therapies require increasingly large and expensive cardiovascularoutcome trials to assess their potential impact on MACE and to obtain regulatory approval. For many disease areas, nearly a half of drugs are approved by the U.S.
Newly included risk factors— untreated vision loss and high LDL cholesterol —underscore the critical role of these elements in maintaining cognitive health. The Cholesterol Connection Cholesterol’s recognition as a risk factor for dementia marks a pivotal advancement in understanding, preventing, and delaying cognitive decline.
BackgroundSome clinical dyslipidemia cases do not respond to statins, known as statin-resistant familial hypercholesterolemia (SR-FH), in which patients are under a high cardiovascular risk despite statin therapy. Therefore, novel therapeutic alternatives are required.
Ballantyne, MD , emphasized that while fellows may consider prevention “boring,” it is crucial for avoiding resource-intensive late-stage cardiovasculardisease (CVD). He highlighted that cardiovascular health is essential for cognitive health, noting the common occurrence of vascular dementia.
Only when you have a clear idea of those three factors can you decide whether or not to take a medication to lower your LDL cholesterol. I use statins in the question posed above because that is what most people think and, in fact, what they will start with when looking to lower their LDL cholesterol with a medication. Not zero risk.
The overwhelming prevailing opinion among Cardiologists (including from our own Heartbeat Cardiology team w/hundreds of combined years of experience treating cardiovasculardisease) is that people can benefit from adopting a Mediterranean diet, so let’s dive in and understand what that really means.
VA sites work with an AHA QI consultant to develop and deploy a local quality improvement plan to help overcome site specific barriers preventing Veterans from achieving optimal cholesterol levels. As this program is further implemented in our institution, we expect improvement in patient outcomes and prognosis.
Circulation: Cardiovascular Quality and Outcomes, Volume 16, Issue 11 , Page e009609, November 1, 2023. mg/dL,P=0.53), total cholesterol (191.2 mg/dL,P=0.53), total cholesterol (191.2 Further studies are needed to explore potential pathways between adverse cardiovasculardiseaseoutcomes and marijuana use.
An elevated Lp(a) is the most common genetic cholesterol disorder impacting 10-20% of the population. Everyone should have an Lp(a) blood test at least once, but this is an absolutely must-do test if you have an early family history of heart disease. Subscribe now 1 ODYSSEY Outcomes Committees and Investigators.
The Takeaway Years of studies have shown that people with high Lp(a) have worse cardiovascularoutcomes, and this new research adds solid particle-level evidence showing why this is the case, while further supporting the need for Lp(a)-lowering therapies.
Engaging in exercise can significantly contribute to maintaining a healthy heart and reducing the risk of cardiovasculardiseases. Reducing Risk Factors Exercise helps manage and reduce risk factors associated with heart disease, such as high blood pressure, high cholesterol levels, obesity, and diabetes.
Background:Adherence to the American Heart Association's Life’s Essential 8 (LE8) reduces the risk of cardiovasculardisease. The independent variable or “exposure” was the LE8 score, which was based on data on blood pressure, blood glucose and cholesterol, body mass index, smoking, physical activity, sleep duration and diet.
IntroductionAtherosclerosis, the occlusion of arteries due to the accumulation of fatty substances, cholesterol, calcium, and fibrin in the arterial walls, can result in reduced blood flow and a subsequent decrease in oxygen delivery to the organs supplied by the affected artery, including the brain.
If you separate those with a significantly elevated Lp(a) (>50mg/dl) and a normal Lp(a) by levels of healthy lifestyle, you see major differences in outcomes. Better lifestyle factors significantly reduced the risk of coronary artery disease, but even with an optimal lifestyle pattern, there was a small increase in risk 2.
Lastly, insufficient sleep is also a massive health liability, leading to cardiovasculardisease, diabetes, and cognitive decline. What’s the best way to spend our time when health is the outcome of interest? Barely 25% of adults meet the minimum 150 minutes of moderate to vigorous physical activity each week.
Dozens if not hundreds of (albeit observational) studies have linked a short sleep duration to a number of health conditions including type 2 diabetes and cardiovasculardisease. A new study used wearable sleep data to show that several chronic diseases are associated with how we sleep.
However, there’s not great evidence that multivitamins benefit specific health outcomes. This hypothesis was studied in a randomized controlled trial known as the COcoa Supplement and Multivitamin Outcomes Study or COSMOS. Nutritional insurance? A health- and longevity-boosting powerhouse? Perhaps not.
The app also recorded other significant heart health risk factors, such as cholesterol, weight, and physical activity via integration with external sources including electronic medical records and fitness trackers. Change in blood pressure (BP), LDL cholesterol, and weight were evaluated from baseline to follow up.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovasculardisease ( CVD ) in National Health Service (NHS) clinical practice. Prevention is at the heart of what we do as GPs and risk assessment underpins that.
Atherosclerosisa key driver of cardiovasculardisease (CVD)continues to be a significant global health issue. These cases are particularly challenging because traditional prevention strategies, which target known risks like high LDL cholesterol, hypertension, diabetes, and smoking, may not apply.
Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovasculardisease affecting up to 20% of the world’s population. Median percentage reduction in Lp(a) of 90% or greater were observed for both doses at week 36.
A new peer-reviewed study published in the Journal of the American Heart Association , JAHA, found that Hello Heart’s digital heart health program was associated with reductions in blood pressure (BP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and weight. statins). .
More than 70% of patients with atherosclerotic cardiovasculardisease (ASCVD) are still not achieving their LDL-C target, so there remains a vast unmet need among high-risk patients for more varied and effective treatment options. Raised cholesterol; [cited 2024 May 15. million deaths worldwide annually. 4 Pirillo A, et al.
BackgroundObesity and hypercholesterolemia independently increase cardiovasculardisease risk. ResultsIn people with obesity, bempedoic acid resulted in placebocorrected reductions in lowdensity lipoprotein cholesterol of 22.5% months in 6177 patients with baseline body mass index 30 kg/m2.ResultsIn and hsCRP of 23.2%
BACKGROUND:Although low-density lipoprotein cholesterol (LDL-C) remains the primary cholesterol target in clinical practice in children and adults, non–high-density lipoprotein cholesterol (non–HDL-C) has been suggested as a more accurate measure of atherosclerotic cardiovasculardisease (ASCVD) risk.
Coronary artery disease is caused by the retention of a cholesterol particle in the artery wall. But if a retained cholesterol particle is the spark. Insulin resistance and diabetes may not ‘ cause ’ coronary artery disease, but they are huge accelerants. But they don’t guarantee the outcome.
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).
When stress is included in the risk factor profile for a future heart attack, it comes in third on the list after abnormal cholesterol and smoking 1. Regardless of what is driving the effect, it is clear that experiencing high levels of stress is associated with worse outcomes. The link is real. For both acute and chronic stress.
CLEAR Trial of Bempedoic Acid Bempedoic acid is an ATP citrate lyase inhibitor, acting upstream of HMGCoA reductase targeted by statins, and reduces LDL cholesterol levels. CLEAR trial had patients for both primary and secondary prevention of cardiovasculardisease. Median follow up was for 40.6 There was 29.2 N Engl J Med.
But resistance training hasn’t been the focus when it comes to improving cardiovascular health and preventing/reversing cardiovasculardiseases (CVDs) — that honor goes to aerobic exercise training, for which the cardiovascular benefits are well-established and vast. The answer is yes.
But resistance training hasn’t been the focus when it comes to improving cardiovascular health and preventing/reversing cardiovasculardiseases (CVDs) — that honor goes to aerobic exercise training, for which the cardiovascular benefits are well-established and vast. The answer is yes.
Cardiovasculardiseases (CVD) affect nearly half of all American adults, and in addition to their impact on health outcomes, they have significant economic implications. are associated with these conditions, the largest across all disease categories. 17% of all annual healthcare costs in the U.S.
Background:Aortic stiffness, assessed as carotid-femoral pulse wave velocity, provides a measure of vascular age and risk for adverse cardiovasculardiseaseoutcomes, but it is difficult to measure. Hypertension, Ahead of Print. 1.82] per SD;P<0.0001). 1.82] per SD;P<0.0001).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content